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Background. Cyclophosphamide (CPM) is still considered to be the first-line treatment for many life-threatening autoimmune conditions. It does, 
however, carry a significant risk of serious adverse events, especially infections. At present CPM is administered as either a daily oral dose (DOC) or 
an intravenous pulse (PIVC). There is uncertainty regarding the safety profiles of both regimens in settings with a high burden of infectious diseases.
Objective. To compare the frequency and nature of adverse events related to the use of DOC and PIVC in such a setting.
Methods. A cohort of patients treated with CPM for autoimmune diseases at Tygerberg Academic Hospital, Cape Town, South Africa, from 
1 January 2008 to 31 May 2013 was studied. We compared participants receiving DOC and PIVC with regard to disease characteristics and 
the occurrence of major adverse events.
Results. A total of 134 participants (92 DOC and 42 PIVC) were included. Participants in the DOC group were treated for longer (174 v. 
101 days; p<0.01) and with higher cumulative doses (17 276 v. 3 327 mg; p<0.01). Risk of infection was similar in the two groups, although 
there were 6 deaths from leucopenic sepsis in the DOC group (v. 0; p=0.18). Nadir leucocyte counts were also lower in the DOC group 
(median 3.8 v. 5.3 × 109/L; p=0.02).
Conclusion. Infection rates in the two groups were similar, but DOC was associated with longer treatment duration, greater cumulative 
CPM doses and more severe leucopenia. If resources allow and available literature provides support for efficacy, consideration should be 
given to greater use of PIVC.
S Afr Med J 2015;105(3):209-214. DOI:10.7196/SAMJ.8785
Autoimmune diseases affecting major organs carry sig-
nificant morbidity and mortality. Immunosuppressive 
therapy with agents such as cyclophosphamide (CPM) 
significantly improves quality of life and survival in 
many patients suffering from such diseases.[1,2]
CPM is still considered to be the first-line treatment for many 
life-threatening autoimmune conditions owing to its well-established 
therapeutic benefits. It does, however, carry a significant risk of 
severe adverse events including cytopenias, infections, infertility 
and bladder toxicity. At present CPM is administered either as a 
daily oral dose (DOC) or as an intravenous pulse at various intervals 
(PIVC). The optimal dosing route and regimen remain controversial, 
especially in the treatment of lupus nephritis.
Large head-to-head trials comparing DOC with PIVC are lacking. 
Many opinions exist on the optimal dosing regimen, based on 
small studies or indirect conclusions from larger studies. Overall 
it seems that DOC has the advantages of lower cost, simpler 
administration and avoidance of high-dose exposure should the drug 
be inappropriately administered.[3,4] PIVC has the advantage of a 
reduced incidence of short- and long-term adverse events and avoids 
the need for daily compliance with treatment. Data regarding the 
comparative efficacy of the two regimens are conflicting and briefly 
discussed below.
Total drug costs for treatment regimens are lower for DOC than for 
PIVC. PIVC also requires allocated space, consumables and personnel 
to administer the infusion. Patients need to take time off work and 
have additional travel expenses, which all contribute to the overall 
cost of this regimen.[3,4]
Although DOC is associated with an increase in long-term side-
effects, adverse events due to inappropriate dosing are more easily 
managed. Examples include administration when a contraindication 
exists, mistaking sepsis for a flare of disease or not adjusting doses 
for renal function. Reducing or omitting further oral doses under 
these circumstances, which cannot be done with PIVC, reduces the 
toxicity.[4]
Austin et al.[5] initially published data in 1986 supporting superior 
treatment outcomes and reduced side-effect profiles with the use 
of PIVC as opposed to DOC in patients with lupus nephritis. This 
led to PIVC becoming the standard treatment in lupus nephritis, 
with fewer subsequent trials and recommendations that include 
DOC.[3,6] This practice is now contested, as subsequent trials[4,7,8] 
and a recent Cochrane review[9] showed no difference in outcomes 
or adverse events. An increased tendency to relapse has also been 
shown in patients with lupus nephritis treated with PIVC.[10] DOC 
was associated with a higher frequency of adverse events in the same 
study. Another small trial showed a slightly larger increase in serum 
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albumin in patients with membranous nephropathy treated with 
PIVC in comparison with DOC.[11]
Trials in antineutrophil cytoplasmic antibody (ANCA)-associated 
vasculitides have also suggested equal to increased ability of PIVC 
to induce remission compared with DOC, but a greater tendency 
towards relapse.[12-14] Episodes of leucopenia and infection were less 
frequent in ANCA-associated vasculitides treated with PIVC.[14-17] 
Increased gonadal toxicity with oral CPM has also been shown in 
patients treated for ANCA-associated vasculitides.[18] Decreased 
toxicity with PIVC is thought to be due to the lower cumulative CPM 
doses used.
No difference in outcomes has been shown between the two 
regimens in treating pulmonary involvement in scleroderma.[19]
The use of CPM in a resource-constrained and infectious diseases-
burdened environment, as in our setting at Tygerberg Academic 
Hospital (TBAH), Cape Town, South Africa, has unique challenges 
and considerations in respect of cost, efficacy and safety. Cost of 
treatment to hospitals, lack of allocated space and trained personnel 
to administer intravenous medication, patients’ ability to travel to a 
tertiary setting to receive treatment, compliance with treatment and 
follow-up, access to healthcare in the event of drug toxicity, and the 
overall increased burden of infectious diseases associated with a low 
socioeconomic environment are all factors to consider in choosing an 
appropriate treatment plan.
Of special concern in our setting is safety. The high prevalence 
of tuberculosis (TB) in communities serviced by TBAH[20] and 
exposure to overpopulated and unhygienic environments can 
significantly endanger patients should they become severely 
immunosuppressed. To our knowledge, no studies comparing DOC 
and PIVC are available that address these safety issues when CPM 
is used in such settings.
Clinicians at TBAH make use of both intravenous pulse and 
oral regimens of CPM for the treatment of autoimmune diseases. 
Treatment choice is largely based on the condition treated and the 
preference of the discipline involved in initiating treatment (e.g. 
lupus nephritis is generally treated with DOC by nephrologists, while 
vasculitis and other severe systemic complications of connective 
tissue diseases are treated with PIVC by rheumatologists). As a 
general guideline, DOC is initiated at a dose of 1.5 mg/kg and PIVC 
at 750 mg/m2, and then titrated according to disease severity and 
leucocyte count. Serious adverse events related to therapy have 
been encountered with both regimens, but the overall prevalence, 
differences in frequency and spectrum of adverse events between the 
two treatment regimens are not known.
Objective
Our primary objective was to compare the frequency and nature of 
adverse events related to the use of oral and intravenous CPM in 
patients with autoimmune diseases.
Methods
A retrospective cohort study was conducted at TBAH to compare 
patients treated with DOC with those who were treated with PIVC. 
Data were extracted from hospital records of adult patients (>18 
years) suffering from autoimmune diseases treated with CPM. 
Pharmacy records were used to identify all patients who started 
treatment between 1 January 2008 and 31 May 2013. Participants 
were only included if they had been on treatment with CPM for at 
least 1 month, unless adverse events due to CPM occurred earlier, 
in which case the participant was also included. Patients who had 
received CPM for indications other than autoimmune disease (e.g. 
chemotherapy, transplant recipients) were excluded. Patients on 
treatment for purely neurological diseases were also excluded owing 
to the different dosing regimens and treatment duration used.
Data collected included demographics, comorbid disease, mass, 
diagnosis and disease involvement, duration of disease prior to CPM 
initiation, treatment prior to CPM initiation, baseline leucocyte 
and neutrophil counts, indication for CPM therapy, initial dosage, 
subsequent adjustment to dosing and indication for changes, 
cumulative total drug dose, concurrent immunosuppressive drug use, 
use of preventive therapy (isoniazid, co-trimoxazole, contraception 
and gonadal protection), documentation of counselling regarding 
contraception, occurrence of major side-effects and discontinuation 
due to drug toxicity. Data collected on side-effects included 
cytopenias, infections, bladder toxicity and infertility. Adverse events 
were reported and graded according to the Common Terminology 
Criteria for Adverse Events guidelines.[21]
Data were captured on a Microsoft Excel spreadsheet and analysed 
using Statistica version 11. The two groups were compared with 
regard to patient characteristics, disease profiles and risk factors for 
developing major side-effects. Continuous variables were analysed 
using the Mann-Whitney U-test, while categorical data were analysed 
using the χ2 and Fisher’s exact tests. A significance level of 5% was 
used throughout.
The study was approved by the Health Research Ethics Committee 
of Stellenbosch University (protocol No. S13/07/121). Owing to the 
retrospective nature of the study, the difficulty in tracing individual 
participants and the low risk to the participants, a waiver of informed 
consent was granted. Data were collected on standardised capture 
sheets using study codes assigned to each participant. Codes linking 
confidential data to the identity of the participants were kept 
separately and securely.
Results
After exclusion of oncology patients, 221 subjects were identified. A 
total of 134 participants were included in the study, 92 in the DOC 
group and 42 in the PIVC group. Eighty-seven subjects were excluded 
for reasons that included treatment for non-rheumatological disease, 
pharmacy errors and missing records, early withdrawal of treatment 
not related to drug side-effects, failure to follow up after initiation of 
treatment, concomitant participation in other drug trials, or receiving 
both PIVC and DOC.
The characteristics of the participants are summarised in Table 1. 
There were no significant differences between the groups in terms 
of age, mass, comorbid disease (HIV and diabetes mellitus) and 
leucocyte count at baseline. Overall, participants were young (mean 
age 34 years) with a female predominance (74.6%), especially in the 
PIVC group (85.7 v. 69.6%; p=0.03).
As expected, there was a marked difference in disease spectrum 
between the two groups, both in terms of primary diagnosis and 
organ involvement.
The indications for starting CPM varied significantly. The most 
frequent indication in the DOC group was class IV lupus nephritis 
(32.6%), followed by non-lupus-related renal disease including 
nephrotic syndrome (27.1%) and rapidly progressive (RPGN) or 
crescentic glomerulonephritis (GN) (21.7%). The most frequent 
indication in the PIVC group was neuropsychiatric lupus (45.2%), 
followed by interstitial lung disease due to various autoimmune 
diseases (28.6%), and lupus myocarditis (28.6%).
A total of 676 patient-months of treatment were observed. 
Treatment details are summarised in Table 2. Participants in the PIVC 
group were treated for significantly shorter periods (mean 101 v. 174 
days; p<0.01) and had much lower mean cumulative doses (3 327 v. 
17 276 mg; p<0.01).
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Table 1. Participant baseline characteristics      
  All (N=134) DOC (N=92) PIVC (N=42) p-value
Gender, n (%)  
M 34 (25.4) 28 (30.4) 6 (14.3) 0.03
F 100 (74.6) 64 (69.6) 36 (85.7)  
Age (years), mean (SD) 34.0 (12.7) 34.2 (13.3) 33.4 (11.4) 0.95
Mass (kg), mean (SD) 69.5 (18.4) 70.5 (18.0) 67.0 (19.5) 0.37
Comorbid disease, n (%)  
Diabetes mellitus 15 (11.2) 9 (9.8) 6 (14.3) 0.44
HIV 5 (3.7) 5 (5.4) 0 (0.0) 0.12
Primary diagnosis, n (%)  
SLE 63 (47.0) 41 (44.6) 22 (52.4) 0.55
Membranous GN 16 (11.9) 16 (17.4) 0 (0.0) *
Mesangiocapillary GN 7 (5.2) 7 (7.6) 0 (0.0) *
SLE/systemic sclerosis overlap 5 (3.7) 3 (3.3) 2 (4.8) *
Crescentic GN 5 (3.7) 5 (5.4) 0 (0.0) *
IgA nephropathy 5 (3.7) 5 (5.4) 0 (0.0) *
Systemic sclerosis 8 (6.0) 2 (2.2) 6 (14.3) *
Granulomatosis with polyangiitis 11 (8.2) 5 (5.4) 6 (14.3) *
FSGS 2 (1.5) 2 (2.2) 0 (0.0) *
Goodpasture’s syndrome 1 (0.8) 1 (1.1) 0 (0.0) *
Mesangioproliferative GN 3 (2.2) 3 (3.3) 0 (0.0) *
Minimal-change nephropathy 2 (1.5) 2 (2.2) 0 (0.0) *
Eosinophilic granulomatosis with polyangiitis 1 (0.8) 0 (0.0) 1 (2.4) *
SLE/rheumatoid arthritis overlap 1 (0.8) 0 (0.0) 1 (2.4) *
SLE/dermatomyositis overlap 1 (0.8) 0 (0.0) 1 (2.4) *
SLE/polymyositis overlap 1 (0.8) 0 (0.0) 1 (2.4) *
Rheumatoid arthritis 1 (0.8) 0 (0.0) 2 (4.8) *
Vasculitis of unknown cause 1 (0.8) 0 (0.0) 1 (2.4) *
Indication for CPM, n (%)  
RPGN/crescentic GN other than lupus 25 (18.7) 20 (21.7) 5 (11.9) 0.18
Nephrotic syndrome other than lupus 25 (18.7) 25 (27.2) 0 (0.0) <0.01
Vasculitis 4 (3.0) 0 (0.0) 4 (9.5) 0.01
Class III lupus nephritis 5 (3.7) 5 (5.4) 0 (0.0) 0.12
Class IV lupus nephritis 31 (23.1) 29 (31.5) 2 (4.8) <0.01
Class V lupus nephritis 7 (5.2) 5 (5.4) 2 (4.8) 0.87
Interstitial lung disease 20 (14.9) 8 (8.7) 12 (28.6) <0.01
Lupus myocarditis 16 (11.9) 4 (4.4) 12 (28.6) <0.01
Eye disease (granulomatosis) 1 (0.8) 1 (1.1) 0 (0.0) 0.50
Neuropsychiatric lupus 21 (15.7) 2 (2.2) 19 (45.2) <0.01
Diagnosis to initiation of CPM (days), mean (SD) 23.3 (44.8) 17.4 (42.2) 36.2 (48.1) 0.04
Duration of disease prior to CPM initiation (months), n (%)  
0 - 3 70 (52.2) 51 (55.4) 19 (45.2) 0.04
3 - 12 19 (14.2) 16 (17.4) 3 (7.1) 0.04
>12 45 (33.6) 25 (27.2) 20 (47.6) 0.04
Leucocyte count at baseline (× 109/L), mean (SD) 9.9 (7.7) 9.2 (4.3) 11.4 (11.9) 0.72
Initiation dose (mg/kg), mean (SD)†   1.6 (0.4) 10.3 (4.4)  
SD = standard deviation; M = male; F = female; SLE = systemic lupus erythematosus; FSGS = focal segmental glomerulosclerosis.
*Owing to low frequency of observations, p-values not determined.
†No comparison made between DOC and PIVC owing to different dosing regimens.
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The most frequent indication for stopping 
therapy was the successful completion of 
induction therapy. This was significantly 
more frequent in the PIVC group, while 
cessation of treatment due to treatment 
failure was more frequent in the DOC group 
(Table 2). Loss to follow-up, infection and 
leucopenia were also frequent reasons for 
discontinuation of treatment in both groups. 
There were nine patients remaining on CPM 
at the time the study concluded, while one 
patient had requested to be transferred to a 
private physician for further management.
Prescription of prophylactic antimicrobials 
was consistently achieved, with 91.8% and 
94.8% of all participants receiving isoniazid 
and co-trimoxazole, respectively. There 
was no difference between the groups. All 
patients received concomitant prednisone. 
Only 43.3% of the participants who required 
contraception were documented to have 
been prescribed contraceptive therapy.
A total of 64 episodes of infection were 
documented, of which 37 were considered 
serious and required hospitalisation. The 
profile of infections is illustrated in Fig. 
1. There were no statistically significant 
differences in the number of infections (42 
v. 22; p=0.53) or hospitalisations (25 v. 12; 
p=0.12) between the DOC and PIVC groups. 
The most frequent infection was urinary 
tract infection, followed by pneumonia. The 
most common opportunistic infection was 
herpes zoster in the PIVC group and CMV 
pneumonitis in the DOC group. There were 
no new cases of TB diagnosed in either group. 
Infections occurred early during therapy 
(median 57.5 days) in both groups, with no 
significant difference between the groups 
(63.0 v. 55.0 days; p=0.72), but occurred 
at a higher cumulative dose at the time of 
infection in the DOC group (7 964  mg v. 
2 126 mg; p<0.01).
Overall, 61.2% of all participants (59.8% of 
the DOC group and 64.3% of the PIVC group; 
p=0.70) had one or more treatment-related 
adverse events (infection or leucopenia). The 
relative risk for developing an adverse event 
in the DOC group v. the PIVC group was 
0.93 (95% confidence interval 0.70 - 1.23).
Over a third (38.1%) of participants 
developed one or more infections during 
CPM therapy. In the DOC group, 35.9% of 
participants developed infections compared 
with 42.9% in the PIVC group (p=0.45). The 
overall risk of a participant having one or 
more hospitalisations as a result of serious 
infection was 24.6%; this was slightly higher 
in the DOC group (26.1 v. 21.4%; p=0.67).
In the DOC group, six participants (6.5%) 
died due to leucopenia-related sepsis. There 
were no treatment-related deaths recorded 
in the PIVC group. This difference was not 
statistically significant (p=0.18). Treatment-
related deaths are summarised in Table 3.
Because the frequency of monitoring of 
leucocyte counts was highly variable, we 
determined the proportion of participants 
who became leucopenic at any time during 
therapy, rather than the leucopenia event rate. 
The lowest recorded leucocyte counts were 
significantly lower in the DOC group, with a 
median of 3.8 v. 5.3 × 109/L (p=0.02) (Table 4). 
Leucopenia also occurred later in the DOC 
group than in the PIVC group (99 v. 76 days; 
p=0.04) and at higher cumulative doses (mean 
3 542 v. 1 929 mg; p<0.01). Notably, neutrophil 
counts were infrequently done.
Comparing the DOC and PIVC groups, 
51.1% v. 33.3% (p=0.06) of participants 
developed leucopenia during treatment. The 
mean duration of leucopenia before the CPM 
dose was adjusted or the drug stopped was 
5 days, with a maximum delay of up to 
28 days. However, delays in stopping CPM 
appeared not to have contributed to any of 
the leucopenia-related deaths.
Discussion
Adverse events due to the use of CPM 
were frequent in both groups, emphasising 
Table 2. Treatment characteristics      
  All (N=134) DOC (N=92) PIVC (N=42) p-value
Treatment duration (days), mean (SD) 151.4 (116.3) 174.0 (127.9) 100.9 (61.1) <0.01
Cumulative dose (mg), mean (SD) 12 903.7 (12 087.5) 17 275.5 (12 210.7) 3 327.4 (2 489.3) <0.01
Cumulative dose (mg/kg), mean (SD) 193.9 (198.0) 262.6 (205.5) 46.7 (32.5) <0.01
Indication to stop treatment, n (%)  
Lost to follow-up 14 (10.5) 9 (9.8) 5 (11.9) 0.71
Infection 15 (11.1) 10 (10.9) 5 (11.9) 0.86
Treatment failure 16 (11.9) 15 (16.3) 1 (2.4) 0.02
Completion of induction 61 (45.5) 36 (39.1) 25 (59.5) 0.02
Leucopenia 16 (11.9) 13 (14.1) 3 (7.1) 0.25
Transferred 1 (0.9) 0 (0.0) 1 (2.4) 0.14
Not stopped 9 (6.7) 8 (9.0) 1 (2.4) 0.18
Fig. 1. Infections during CPM treatment. (UTI = urinary tract infection; URTI = upper respiratory tract 
infection; SBE = subacute bacterial endocarditis; CMV = cytomegalovirus; MOTT = mycobacterium 
other than TB.)
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the reality that CPM is a potent cytotoxic drug that should be 
prescribed with caution and with careful follow-up and monitoring. 
To our knowledge this is the first study from a developing country 
comparing DOC and PIVC. Other studies have reported leucopenic 
episodes in 17 - 26% of PIVC and 19 - 45% of DOC participants[7,14,16] 
and infection in 10 - 39% of PIVC and 14 - 57% of DOC participants. 
Similar infection rates were observed in our study (DOC 36% v. PIVC 
43%), while leucopenia was more frequent (DOC 51% v. PIVC 33%).
In our setting, it appears that PIVC may be safer than DOC. Six 
treatment-related deaths occurred in the DOC group and none in the 
PIVC group, although this difference was not statistically significant. 
DOC was also associated with more frequent and more severe 
leucopenia, and with a non-significant increase in hospitalisations 
suggesting more serious infections, while PIVC was associated with a 
non-significant increased frequency of all infections.
The participants in the DOC group were treated for a significantly 
longer time and may therefore have been more likely to experience 
adverse events. Most adverse events in our study, as in other 
studies,[16] occurred early in the course of treatment.
It is important to appreciate that in our study the condition being 
treated determined the route of CPM administration and, by default, 
also selected for differences in management. Different teams of 
clinicians and differences in follow-up and monitoring may therefore 
have affected the results.
The high cumulative doses used in the DOC group could have 
increased efficacy, but are the likely explanation for the increased risk 
of leucopenia associated with DOC. Another factor was that PIVC 
was only administered if there was an acceptable leucocyte count 
on the day of each pulse infusion. With DOC, a leucocyte count 
before every dose is not feasible. There was some variability in the 
frequency of leucocyte counts done in the DOC group. Counts were 
not always available at the time of follow-up, and were occasionally 
only reacted to at the next visit. PIVC is perceived as high-dose 
intravenous chemotherapy and instinctively enforces caution and 
meticulous follow-up. DOC may be perceived as less potent and not 
elicit the same careful follow-up by those not familiar with its serious 
side-effect profile.
This study has identified the need to critically evaluate the current 
practice of CPM administration at our institution. Most drug-
attributable deaths and infections occurred early in the course of 
treatment; it is therefore strongly suggested that leucocyte counts be 
monitored more frequently soon after initiation of CPM, and that 
same-day leucocyte counts be available at all follow-up visits. The 
paucity of neutrophil counts was disappointing. Differential leucocyte 
counts should be requested routinely, as severe neutropenia may be 
masked by other cell lines in mild leucopenia if only total leucocyte 
counts are requested.
An unexpected finding was that no new episodes of TB were 
documented in any participant. This is especially noteworthy 
considering the high prevalence of TB of up to 32/1 000 population 
in communities serviced by this hospital.[20] This suggests that current 
screening protocols for active TB prior to initiation of CPM and the 
regular use of isoniazid prophylaxis are effective. Cyclomegalovirus 
(CMV) pneumonitis was a significant opportunistic infection in the 
DOC group and a cause of leucopenia-associated death. Patients 
on CPM who present with leucopenic sepsis should be screened 
and treated early (and probably empirically) for CMV infection. 
Current evidence to support prophylactic antiviral treatment for 
CMV is lacking, and it is unlikely to be cost-effective in a resource-
constrained setting. Consideration could be given to determining 
patients’ CMV status prior to CPM initiation. Knowing the baseline 
CMV serology and viral load may aid in the decision whether or 
not to treat for suspected CMV disease when patients on CPM 
present with leucopenia and signs of infection. However, the cost-
effectiveness of such an approach would need to be determined.
Alarmingly, almost 10% of participants initiated on CPM were 
lost to follow-up immediately after discharge from hospital. Another 
10% were lost to follow-up later in the study. Considering the poor 
prognosis of the underlying conditions if left untreated, it is possible 
that many of these patients died as a result of their autoimmune disease. 
However, adverse events due to CPM are probably a contributing factor. 
The need for excellent record keeping and tracking of patients on CPM 
must be emphasised, and clinic staff should be prompted to contact 
patients should a follow-up visit be missed.
If resources allow, consideration should be given to the greater use 
of PIVC where its use in the treatment of the specific condition in 
Table 3. Leucopenia-related deaths
Age (years), 
gender Diagnosis 
Duration of 
treatment (days)
Lowest leucocyte 
count (× 109/L) Cause of death
41, F Mesangiocapillary GN with crescents 59 0.79 Varicella zoster pneumonia
21, F SLE with class IV nephritis and myocarditis 21 3.31 Severe pneumonia and renal failure*
23, F SLE with class IV nephritis 69 0.54 CMV pneumonitis
51, F Crescentic GN 25 0.65 Neutropenic sepsis (unknown source)
37, F SLE with class IV nephritis and myocarditis 31 1.58 CMV pneumonitis
30, F SLE with class IV nephritis 49 0.34 Overwhelming Acinetobacter baumannii 
sepsis†
SLE = systemic lupus erythematosus; CMV = cytomegalovirus.
*Subject had renal failure, which significantly contributed to death.
†Leucocyte count at baseline 2.66 × 109/L.
Table 4. Lowest recorded leucocyte count in participants who 
developed leucopenia 
  
Severity class*
All
n (%)
DOC
n (%)
PIVC
n (%)
1 (3.01 - 4.00) 20 (32.8) 14 (29.8) 6 (42.9)
2 (2.01 - 3.00) 13 (21.3) 8 (17.0) 5 (35.7)
3 (1.01 - 2.00) 13 (21.3) 11 (23.4) 2 (14.3)
4 (<1.00) 9 (14.8) 8 (17.0) 1 (7.1)
5 (death) 6 (9.8) 6 (12.8) 0 (0.0)
*Leucocyte count (× 109/L) according to Common Terminology Criteria for Adverse Events.[21] 
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question is supported by current literature. This would be especially 
useful in cases where compliance with daily medication is in doubt. 
Owing to the differences in conditions treated, we did not evaluate the 
efficacy of treatment, which might be the decisive factor in choosing 
between DOC and PIVC. As pointed out, in many conditions there 
is a lack of compelling evidence regarding efficacy to preferentially 
advocate the use of DOC or PIVC.
Study limitations
This study relied on the completeness and accuracy of TBAH’s 
pharmacy database to identify all patients receiving CPM during the 
study period. The study was retrospective with data extracted from 
patient records. A heterogeneous group of conditions were included 
and allocation to PIVC and DOC was not random but determined 
by the disease process and the preference of the clinicians involved 
(rheumatology v. nephrology). The primary disease process as well as 
differences in practices by clinicians are likely to influence treatment 
outcomes and risk of adverse events. The long-term complications of 
CPM (e.g. bladder toxicity, infertility) were not studied.
Conclusion
This study has provided new data on adverse events due to CPM 
in a developing world setting with a very high burden of infectious 
diseases. We found that a greater proportion of participants receiving 
DOC developed severe leucopenia, which may be explained by 
the higher cumulative doses taken over longer periods. There was, 
however, no significant difference in the proportions of participants 
who developed infections or required hospitalisation as a consequence. 
Six participants in the DOC group and none in the PIVC group died 
as a result of complications of CPM treatment; this difference was not 
statistically significant.
Local randomised trials are needed to compare PIVC and DOC 
where follow-up is standardised and where homogeneous groups 
of conditions are compared. This will provide not only more data 
with regard to safety, but also much-needed data on differences in 
treatment outcomes.
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